Vertex Pharmaceuticals Incorporated
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vertex Pharmaceuticals Incorporated
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
The Phase I trial of IONIS-ENAC-2.5Rx for cystic fibrosis represents the first time an antisense medicine delivered directly to the lung has shown a significant reduction in ENaC messenger RNA levels.
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
- Other Names / Subsidiaries
- ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics